{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:27:27Z","timestamp":1790566047564,"version":"4.1.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Respiratory viral infections (RVIs) are of major clinical importance in immunocompromised patients and represent a substantial cause of morbidity and mortality in patients with hematologic malignancies and those who have undergone hematopoietic cell transplantation. Similarly, patients receiving immunotherapy with CD19-targeted chimeric antigen receptor\u2013modified T cells, natural killer cells, and genetically modified T-cell receptors are susceptible to RVIs and progression to lower respiratory tract infections. In adoptive cellular therapy recipients, this enhanced susceptibility to RVIs results from previous chemotherapy regimens such as lymphocyte-depleting chemotherapy conditioning regimens, underlying B-cell malignancies, immune-related toxicities, and secondary prolonged, profound hypogammaglobulinemia. The aggregated risk factors for RVIs have both immediate and long-term consequences. This review summarizes the current literature on the pathogenesis, epidemiology, and clinical aspects of RVIs that are unique to recipients of adoptive cellular therapy, the preventive and therapeutic options for common RVIs, and appropriate infection control and preventive strategies.<\/jats:p>","DOI":"10.1093\/ofid\/ofad166","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T20:06:10Z","timestamp":1679688370000},"source":"Crossref","is-referenced-by-count":13,"title":["Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention"],"prefix":"10.1093","volume":"10","author":[{"given":"Rita","family":"Wilson Dib","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, Texas , USA"},{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Ariza-Heredia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Spallone","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,25]]},"reference":[{"key":"2023041219070674900_","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"2023041219070674900_","first-page":"42","article-title":"Adult survivorship: considerations following CAR T-cell therapy","volume":"23","author":"Buitrago","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-3-319-04220-6_11","article-title":"Infections in patients with leukemia and lymphoma","volume":"161","author":"Morrison","year":"2014","journal-title":"Cancer Treat Res"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1399-3062.2008.00362.x","article-title":"Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Khanna","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"2023041219070674900_","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","article-title":"T cell regeneration after immunological injury","volume":"21","author":"Velardi","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy\u2014a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-141224","article-title":"Hypogammaglobulinemia and infection risk in chronic lymphocytic leukemia (CLL) patients treated with CD19-directed chimeric antigen receptor T (CAR-T) cells","volume":"136","author":"Uy","year":"2020","journal-title":"Blood"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","volume":"62","author":"Dayagi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study","volume":"73","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MCP.0000000000000858","article-title":"Respiratory viral infections in the immunocompromised","volume":"28","author":"Ison","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3324\/haematol.2018.215152","article-title":"Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies","volume":"104","author":"Khawaja","year":"2019","journal-title":"Haematologica"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fmed.2019.00109","article-title":"Drugs for influenza treatment: is there significant news?","volume":"6","author":"Principi","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","article-title":"Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial","volume":"22","author":"Kumar","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1093\/cid\/ciab113","article-title":"DAS181 treatment of severe lower respiratory tract parainfluenza virus infection in immunocompromised patients: a phase 2 randomized, placebo-controlled study","volume":"73","author":"Chemaly","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/JEP.S255211","article-title":"Experimental antiviral therapeutic studies for human rhinovirus infections","volume":"13","author":"Coultas","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2022016089","article-title":"How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies","volume":"140","author":"Chaer F","year":"2022","journal-title":"Blood"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jtct.2022.09.002","article-title":"Revised guidelines for coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022)","volume":"28","author":"Dioverti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","article-title":"Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy","volume":"222","author":"Helleberg","year":"2020","journal-title":"J Infect Dis"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1001\/jama.2022.6876","article-title":"Oral antiviral medications for COVID-19","volume":"327","author":"Petty","year":"2022","journal-title":"JAMA"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3322\/caac.21462","article-title":"Update on infection control practices in cancer hospitals","volume":"68","author":"Ariza-Heredia","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1017\/ice.2020.425","article-title":"Absence of nosocomial influenza and respiratory syncytial virus infection in the coronavirus disease 2019 (COVID-19) era: implication of universal masking in hospitals","volume":"42","author":"Wong","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciw451","article-title":"Universal mask usage for reduction of respiratory viral infections after stem cell transplant: a prospective trial","volume":"63","author":"Sung","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003428","article-title":"Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study","volume":"9","author":"Walti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-022-01300-9","article-title":"Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.idc.2019.02.007","article-title":"Vaccination of the stem cell transplant recipient and the hematologic malignancy patient","volume":"33","author":"Kamboj","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"2023041219070674900_","author":"Khawaja"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869990","article-title":"Long-lasting T cell responses in BNT162b2 COVID-19 mRNA vaccinees and COVID-19 convalescent patients","volume":"13","author":"Hurme","year":"2022","journal-title":"Front Immunol"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2022016166","article-title":"Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients","volume":"140","author":"Oh","year":"2022","journal-title":"Blood"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T\u2014and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2013-12-541359","article-title":"Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2023041219070674900_","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Yanez","year":"2019","journal-title":"Hemasphere"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad166\/49629267\/ofad166.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/4\/ofad166\/49870824\/ofad166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/4\/ofad166\/49870824\/ofad166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T15:52:46Z","timestamp":1702137166000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad166\/7085727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,25]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad166","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,3,25]]},"article-number":"ofad166"}}